Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update
Eva Kimby(Karolinska University Hospital), Emanuele Zucca(Università della Svizzera italiana), Felicitas Hitz(Kantonsspital St. Gallen), Thilo Zander(Luzerner Kantonsspital), Hanne Bersvendsen(University Hospital of North Norway), Michèle Voegeli(Kantonsspital Baselland), Maria Cristina Pirosa(Institute of Oncology Research), Peter de Nully Brown(Copenhagen University Hospital), Hans Hagberg(Uppsala University Hospital), Fatime Krasniqi(University Hospital of Basel), Sämi Schär(Swiss Group For Clinical Cancer Research), Ulrich Mey(Kantonsspital Graubünden), Anastasios Stathis(Princess Margaret Cancer Centre), Stefanie Hayoz(Swiss Group For Clinical Cancer Research), Walter Mingrone(Kantonsschule Olten), Micaela Hernberg(Apple (Israel)), Björn E. Wahlin(Karolinska University Hospital), Urban Novak(University of Bern), Bjørn Østenstad(Oslo University Hospital), Christoph Mamot(Kantonsspital Aarau), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Stefan Dirnhofer(University of Basel), Anna Vanazzi(European Institute of Oncology), Ann‐Sofie Johansson(University Hospital of Umeå), Daniel Rauch(Washington University in St. Louis)
Cited by 4
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791